慢性髓性白血病患者BCR-ABL融合基因的规范化检测及临床应用  

Standardized detection of BCR-ABL mRNA and clinical application in patients with chronic myeloid leukemia

作　　者：秦亚溱[1] Qin Yazhen(Peking University People's Hospital,Peking University Institute of Hematology,National Clinical Research Center for Hematologic Disease,Beijing 100044,China.)

机构地区：[1]北京大学人民医院,北京大学血液病研究所,国家血液系统疾病临床医学研究中心,北京100044

出　　处：《临床荟萃》2021年第10期884-888,共5页Clinical Focus

摘　　要：BCR-ABL融合基因(mRNA)是慢性髓性白血病(CML)的分子标志,靶向BCR-ABL的酪氨酸激酶抑制剂(TKIs)是当前CML治疗的基本药物。BCR-ABL mRNA水平是TKI疗效评估的重要指标,ABL酪氨酸激酶区突变提示耐药机制、指导随后TKIs的选择等治疗策略。规范化的BCR-ABL检测是精准指导临床治疗的前提,是CML患者获得最佳疗效的保证。规范化体现在样本类型、检测内容、实验室检测方案、报告方式等方面,本文结合新近文献探讨了CML患者BCR-ABL定量和突变的规范化检测及临床应用。BCR-ABL mRNA is the molecular marker of chronic myeloid leukemia(CML),and tyrosine kinase inhibitors(TKIs)targeting BCR-ABL mRNA has become the basic drug for CML.BCR-ABL mRNA level is the important indicator for evaluation of TKI efficacy.The mutation in ABL tyrosine kinase domain suggests mechanism of TKI resistance,which could guide the treatment strategy such as the selection of next TKIs.Standardized detection of BCR-ABLmRNA is essential for precisely guiding treatment and the guarantee for CML patients to achieve the best curative effects.Standardization is involved in sample type,testing content,laboratory protocol and report ways.This paper explored the standardized detection of quantification and mutation of BCR-ABL and clinical application in CML patients based on recent literature.

关 键 词：白血病 髓样 慢性 融合蛋白质类 BCR-ABL 受体蛋白质酪氨酸激酶类 规范化 

分 类 号：R733.72[医药卫生—肿瘤]